GlassScriptPhysician profile
Afshine A Emrani
NPI 1356360887
$27,718.73
in general payments reported to CMS, 2019-2025
60 companies · $4,035 in 2025
The $4,035 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,978 · 2020: $2,520 · 2021: $3,158 · 2022: $3,978 · 2023: $5,539 · 2024: $4,511 · 2025: $4,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,958.11 |
| Education | $127.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,799.56 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $3,309.07 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,718.19 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,695.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,238.52 | 2019-2024 | Xarelto |
| Abbott Laboratories | $1,153.38 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $1,058.96 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $938.25 | 2019-2025 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $902.41 | 2019-2025 | |
| Edwards Lifesciences Corporation | $846.01 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Pfizer INC. | $838.40 | 2019-2024 | |
| Novo Nordisk INC | $801.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $768.53 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $750.29 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $719.16 | 2019-2025 | Trelegy Ellipta |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshine Emrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.